Entertainment

Animation Dance E-Sports Entertainment/Celebrity Film Music Radio Restaurants Sports Television Theater Video Virtual Reality
News Release Digital Asset Direct

Media Veterans to FCC: Lawsuits Bolster Claim that FOX & Murdochs Lack Character Required of Public Broadcast License Trustees

Raynor Ave.

Media veterans filed comments with the Federal Communications Commission (FCC), bringing the FCC’s attention to four shareholder derivative lawsuits accusing Fox Corporation's (FOX) Board of Directors of breaching its fiduciary duty. The lawsuits allege that Rupert Murdoch, Lachlan Murdoch, and various officers and directors were complicit in decisions to disseminate false news and operate Fox News outside the bounds of First Amendment protections; and as a result, the company failed to safeguard shareholders from various journalistic integrity issues. The Media and Democracy Project (MAD) filed a motion requesting the FCC to compel FOX to produce key nonpublic discovery from its various lawsuits to ensure full transparency and accountability for its actions. MAD’s motion seeks evidence from the Dominion and Smartmatic litigations, all documents reviewed in the four stockholder derivative lawsuits, and internal communications from FOX Corp-owned television station FOX 29 Philadelphia (WTXF). Duggan-Kristol Derivative Filing The comment submitted by former PBS President and FCC Commissioner Ervin S. Duggan and media veteran and former Weekly Standard Editor William Kristol advances as yet another damning argument in support of the Media and Democracy Project’s (MAD) Petition to Deny the broadcast license renewal application for FOX Corp-owned television station FOX 29 Philadelphia (WTXF). “The pension funds' lawsuits address FOX leadership's willingness knowingly to lie about important matters, and go to the heart of the issue before the FCC,” said William Kristol. “These lawsuits paint the story of a corporation led by the Murdochs that lacks the character expected of a broadcast licensee.” Delaware law allows the plaintiffs to review nonpublic corporate information known as Section 220 material in preparation for drafting a complaint. This nonpublic information goes to the core questions before the commission. One lawsuit details how FOX scrapped processes in place at the Board of Directors level to monitor journalistic integrity issues in 2019. Those policies were only reconsidered in mid-2021 after the Dominion (and pending Smartmatic) litigation was filed, according to the complaint filed by Tredje AP-Fonden and other plaintiffs. The same complaint also raises the issue of whether the Board’s lack of journalistic integrity policies was related in some way to Rupert and Lachlan Murdoch’s desire to stem viewer defection to preserve their influence in conservative politics, which the complaint argues they prioritized above broadcasting the truth. These lawsuits offer critical new evidence from Section 220 material and reflect that FOX shareholders are as troubled by the same core issues that should trouble the Commission. The Duggan-Kristol filing ends by saying the FCC “should not—cannot—don blinders as to the implications that the questions being weighed in [the Delaware Court of Chancery] must have on its judgment as to whether FOX and its Controllers can be trusted to operate broadcast stations in the public interest.” “These lawsuits show the parent corporation of the broadcast licensee showed poor judgment and questionable character in managing a business that—but for FCC licensure—is identical in core objectives and operation of its subsidiary broadcast station,” said Ervin S. Duggan. “We believe firmly that these nonpartisan lawsuits demonstrating bad judgment and suspect character should speak loudly to the Commission.” Two of the four lawsuits filed by pension funds representing workers in New York City, Oregon, Rhode Island, and the Swedish Government, cite MAD’s Petition to Deny as an outcome of the recklessness of the FOX Board’s inability to reign senior leadership in, allowing them to continue to promote lies about the 2020 election. From the Tredje AP-Fonden Complaint: Defendants’ breaches of fiduciary duty have not only resulted in massive economic and reputational damages to the Company and caused untold societal harm, but they also threaten to deny Fox’s ability to continue operating as a broadcast news media business, which is its core business. ( paragraph 308 ) From the New York City Complaint: The Murdochs’ decision to embrace Trump’s claims of a stolen election not only led to the $787.5 million settlement payment to Dominion, but also endangered Fox’s broadcast licenses. ( paragraph 211 ) A copy of the filing from Duggan and Kristol can be found here. Media and Democracy Project Motion for Documents While a great deal of discovery evidence has been produced in the various FOX litigations, this evidence is only available to the FCC and MAD in snippets. The public interest imperative of this proceeding requires a full review of all the evidence to ensure a complete and transparent evaluation of the renewal application and the Commission’s decision to designate a hearing. MAD’s motion seeks the FCC to require FOX to produce a range of nonpublic documents, emails, and testimony related to the following areas: All documents and deposition transcripts submitted or provided in connection with the Dominion and Smartmatic litigations. All documents submitted in the four Delaware Chancery stockholder derivative lawsuits in response to any party’s Delaware Section 220 demand for inspection of books and records. From January 2020 to the present, all documents and written communications between political advertisers, their representatives and advertising agencies concerning political advertising, lowest unit rate charges or requests to purchase advertising on station WTXF-TV. From January 2020 to the present, all written communications from any FOX, Fox Television Stations, LLC or WTXF-TV station employees indicating that the FCC’s electronic filing system was malfunctioning or that an attempt was made to upload WTXF-TV political files but was unsuccessful due to the FCC database not operating properly. A copy of the motion from MAD can be found here. The Media and Democracy Project: MAD is a non-partisan, all-volunteer, grassroots civic membership organization fighting for a more informative and pro-democracy media operating in the public interest. MAD aims to improve our national discourse so that American voters can engage in informed decision-making. As part of that goal, MAD has an interest in the responsibility of journalists and media to report fully, accurately, and fairly on the electoral process and the outcome of elections. Additional information is available at www.MediaAndDemocracyProject.org. Ervin S. Duggan is a veteran of the Lyndon Johnson White House, a former Commissioner of the Federal Communications Commission, and former President of PBS. William Kristol is a veteran political analyst and commentator. He served in senior positions in the Ronald Reagan administration and the George H.W. Bush White House. For two decades, he edited The Weekly Standard magazine, and is now editor at large of The Bulwark and a director of the educational and advocacy group, Defending Democracy Together. Contact Details Aaron Alberico +1 202-744-0786 aalberico@raynoravenue.com Company Website https://www.mediaanddemocracyproject.org/

October 10, 2023 09:10 AM Eastern Daylight Time

Shaquille O’Neal Debuts “Shaq’s Fantasy Lab” on Las Vegas Strip

Fantasy Lab

NBA Hall of Famer and internet beloved Shaquille O'Neal, also known as "Shaq", and Fantasy Lab Las Vegas officially debut “Shaq’s Fantasy Lab” to the public. The entertainment venue and basketball legend announced their partnership on September 18th, appointing O’Neal with the new title of Chief Fantasy Officer “CFO” at Fantasy Lab in Las Vegas. Now locals and incoming travelers can experience Shaq’s Fantasy Lab for themselves. This partnership brings together the limitless world of immersive experiences and the unparalleled charisma of Shaq. “ Fantasy Lab quickly became one of my favorite places to visit when I’m in Las Vegas, so I was excited when the opportunity to get involved presented itself. I’ve loved working with Fantasy Lab’s innovative minds, and can’t wait for everyone to see what we’re doing with the space,” says Shaquille O’Neal. Located at Fashion Show Las Vegas shopping mall, Fantasy Lab is a one-of-a-kind ticketed immersive experience that all ages can enjoy as well as a collection of thoughts, dreams, and emotions brought to life by original technologies that blur the line between science and fiction. A collection of love, fear, hope, heartbreak, and beauty scattered across multiple rooms Enlightenment, Insomnia, Kaleidoscope, Nightmare, Circus, Labyrinth, Stars), each with its own story to tell. “ In both our Mexico City and Las Vegas venues, our goal is to make our visitors leave Fantasy Lab feeling more uplifted than when they walked in. Partnering with Shaq has been the alignment we’ve been searching for due to his genuine enthusiasm for bringing fun into everything he does. Apart from a legendary NBA career, Shaq has been known for his positive and light-hearted character and attitude in everything he does and we know together we can leave a positive mark on our Vegas visitors,” shares Ricardo Franco, co-owner and co-founder of Fantasy Lab. On top of revamping the seven experiential rooms at Fantasy Lab to fit Shaq’s fantasies and larger-than-life personality, Shaq’s Fantasy Lab will also have a full bar and kitchen. Visitors will be able to choose from 2 different experiences, Time to Dream and Midnight Dreams. While visitors can expect the same immersive audio-visual experience with both, Midnight Dreams takes place Wednesday through Sunday from 8 p.m. to close and is designed for the 21 and over crowd in Vegas. It’s a free-roaming experience where guests can explore the seven rooms at their own pace, each with different popular music and original visuals. Guests are also welcome to savor a drink as they roam and absorb the atmosphere. Time to Dream is every day until 8 p.m. and is a family-friendly experience designed to be fun for people of all ages. Guests spend about 10 minutes in each room to fully soak up the experience. Alcohol is not permitted during the day for the Time to Dream experience. For additional information visit shaqsfantasylab.com. To purchase tickets visit Time to Dream and Midnight Dreams. Fantasy Lab LV can also be found on: Facebook and Instagram. About Fantasy Lab Fantasy Lab is an immersive experience, originally in Mexico City and expanded into Las Vegas, that is a collection of thoughts, dreams, and emotions brought to life by original technologies that blur the line between science and fiction. A collection of love, fear, hope, heartbreak, and beauty scattered across multiple rooms, each with its own story to tell. As pioneers of immersive experiences, Fantasy Lab believes in a world where technology provides hope and connection, not disenchantment and isolation, and they are doing their part to make it a reality. Contact Details Eleven11 Media Relations Juliana Martins +1 725-200-3701 juliana@eleven11mediarelations.com Company Website https://fantasylablv.com/

October 10, 2023 09:04 AM Eastern Daylight Time

Image

Meet Your Friendly Neighborhood Knightscope Robot

Benzinga

By Faith Ashmore, Benzinga Click here to learn more about the Knightscope Public Safety Infrastructure Bond. For many decades, people have been imagining how robots would fit into the future. Whether it was Sonny from Isaac Asimov’s I, Robot, the equally awe-inspiring and terror-inducing Terminator, or everyone’s favorite Wall-E, robots have been a part of pop culture for decades. Well, now robots are no longer a thing solely reserved for Hollywood. And better yet, they are helping keep the streets safe without the risk of going rogue. The future is now. In an ever-evolving world, public safety is in need of an upgrade. AI and robotics are part of the solution to create safer public spaces while decreasing human error that can come from human police officers. Knightscope (NASDAQ: KSCP) is a technology company ushering in the dawn of Autonomous Security Robots (ASRs) and working hard to protect U.S. citizens from crime across the country. The company has over a decade of experience and has shown its solutions to be effective. For example, when one of its units was deployed in Huntington Park, Los Angeles County, there were 46% fewer crime reports overall – and they have recently renewed the contract for the 5th year in a row. Knightscope’s success has garnered national attention, and the company has won corporate contracts with major corporations such as PENN Entertainment (NASDAQ: PENN), PG&E (NYSE: PCG), ABM (NYSE: ABM) and Lowe's (NYSE: LOW) The company’s robots are designed to enhance safety and security in various environments, such as corporate campuses, shopping malls and hospitals. Knightscope robots operate autonomously, meaning they can navigate and patrol areas without human intervention. They utilize a combination of sensors, cameras and artificial intelligence algorithms to detect and analyze their surroundings in real time. The robots are equipped with 360-degree cameras, thermal imaging sensors, and license plate recognition capabilities to capture and analyze visual data. They can also detect signals from Wi-Fi and Bluetooth devices, helping to identify potential security threats. The data collected by the Knightscope robots is sent to a central command center through a secure wireless network. The command center operators can monitor the robot's feed, receive alerts for suspicious activity, and control the robot's movements remotely when necessary. The robots were also designed with a large physical presence to serve as a deterrent, as their presence often helps to discourage criminal activity. Knightscope’s influence and reach seem to be on the rise. Just in 2023, the company has made more than 50 announcements including numerous contracts and reports it is on track to double its revenue versus 2022. These contracts further validate the growing demand for Knightscope's robotic solutions as they continue to work through a nearly $5 million backlog of new orders.. The company is also joining the NYPD and MTA in New York City. Their robots will operate within the subway system during the late-night hours of 12:00 a.m. to 6:00 a.m. The K5 robots maintain a balance of effectiveness and approachability, being both engaging and respectful of privacy. Better yet, they were designed to be photogenic, and NYC tourists are sure to get a kick out of the recent development. This deployment signifies the continued expansion of Knightscope's robots to support policing efforts throughout the United States – with the largest city in the country with the largest police department in the country taking the lead Another notable development is the launch of their School Safety Grant Program. This initiative enables individuals to contribute to creating safer learning environments in K-12 schools. By pooling together non-deductible donations, the program aims to partially subsidize schools facing budget constraints, preventing them from implementing Knightscope's advanced security technologies. This endeavor is a powerful way to protect children, faculty, and administrators within educational institutions. The company is currently offering an investment opportunity for interested parties to buy bonds. Over recent years, there has been an increase in the development of robotic technologies for everyday life activities. Positive attitudes towards robots are increasing, and while there are mixed views globally, there is an overall recognition of the potential benefits and positive impact of robot use in society. The demand for robots is only poised to grow. In 2021. The robotics market was valued at $31.38 billion in 2021 and is expected to reach $110.39 by 2030 with a CAGR of 15% from 2022-2030. Knightscope seems well-positioned to capitalize on this growth and be a potential leader in the U.S. market. Click here to learn more about the Rise of the Robots. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 10, 2023 09:00 AM Eastern Daylight Time

Starpax’s Cancer Technology Looks To Address A Major Problem That Chemotherapy And Immunotherapy Haven’t Solved For A Century

Benzinga

By Kimberly Adams, Benzinga The human body has healthy cells that reproduce to replace damaged or missing cells in the tissues. Cancer starts when one of those cells begins to have an abnormal reaction that causes it to reproduce perpetually. It takes approximately one billion of these cancer cells to end up with a ¾-inch tumor. So, imagine how many cancer cells a 2-inch tumor gets. If you don’t kill all these cancer cells, a single cancer cell left could cause the cancer to come back. When tumors grow, blood vessels in the tumor begin to malfunction, becoming chaotic and often collapsing. Drugs and immune cells need blood vessels to reach all cancer cells in a tumor, however, unfortunately, there are regions of the tumor where cancer cells are totally inaccessible. These regions are called hypoxic zones – where the level of oxygen is extremely low – and this is where the cancer stem cells are located. It is very important for a cancer treatment to eliminate cancer stem cells because they are the major driver of metastasis in the patient’s body and resistance to treatment. It is well documented that systemic chemotherapy or immunotherapy fails to reach hypoxia zones to kill cancer stem cells. The reason is simple – if there are no blood vessels to bring drugs or immune cells next to a cancer cell, the counter-tumor action cannot work because drugs or immune cells are not self-propelled to travel by themselves in the interstitial spaces of the tumor tissues. Of course, when the blood vessels in a tumor are not too damaged and hypoxic zones are still absent, patients see treatments showing some efficacy. But the problem is that cancer diagnostics often come too late and hypoxic zones are too often already present in the tumor at the patient’s first exam. This is where Starpax’s never-before-seen extraordinary technology comes in – to address specifically this problem of reaching cancer cells in hypoxic zones. Starpax Magnetodrones™ are self-propelled, meaning they can swim in the interstitial space of tumor tissues without the need for blood vessels. The Magnetodrones are proprietary nonpathogenic Starpax living bacteria (Bn1-S™) developed in-laboratory, conceived to transport FDA-approved anticancer molecules attached to their surface. They are injected directly into the tumor, not in the blood vessels. They are sensitive to very special magnetic fields generated by the Starpax Polartrak™, a medical device invented by Starpax in which the patient is installed. The Polartrak creates unique patented virtual monopole magnetic fields vectors that control the trajectory of the Magnetodrones in 3D with millimetric precision inside the tumor in order to force them to spread throughout the whole volume of the tumor while they release drugs to the cancer cells on their path. Also, the PolarTrak is conceived to create a magnetic sphere around the tumor that keeps the Magnetodrones captive inside the tumor, thus aiming to avoid toxicity to the rest of the patient’s body and typical side effects of systemic treatments that could damage healthy tissues and organs. Another specific characteristic of the Magnetodrones is they are aerotactic – that means they search for a low level of oxygen to be comfortable. The Magnetodrones have been developed to live in a culture media with an excessively low oxygen level which is the same as the oxygen level in a hypoxic zone. So, when they pass by a hypoxic zone, they stop swimming, penetrate and accumulate into it to deliver anticancer drug to stem cells inaccessible by current systemic treatments or even immune cells. Since stem cells do not divide in hypoxia zones – The Magnetodrones bring a specific drug molecule into this area that reverses chemoresistance of the hypoxic zones in order to destroy stem cells. Magnetodrones cannot proliferate in the human body as they die within 60 minutes after the injection because the temperature of the human body is too high for them to survive. Having reached 100% remission rate and no side effects observed in their preclinical studies, Starpax is confident of achieving similar results in its human clinical studies scheduled for the end of the first quarter of 2024. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 10, 2023 09:00 AM Eastern Daylight Time

Sharps Technology (STSS) To Enter The Copolymer Prefillable Syringe Market With Strength And Ahead of Plan Through Pending Manufacturing Facility Acquisition and $400M Nephron Deal

Benzinga

By Meg Flippin, Benzinga Sharps Technology Inc. (NASDAQ: STSS) is pushing into the copolymer prefillable syringe market thanks to a deal with Nephron Pharmaceuticals Corp., a leader in contract manufacturing of generic medications and 503B outsourcing that includes prefillable sterile syringes. Sharps announced the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility for $50 Million. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for Sharps’ next-generation copolymer prefillable syringe systems. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production and subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033. “With this landmark purchase agreement in place for our copolymer prefillable syringes, we will accelerate the realization of our shared goals, transition the company to revenue, and propel Sharps into a new phase of growth and sustainability,” commented Robert Hayes, CEO of the medical device and pharmaceutical packaging company specializing in developing and manufacturing copolymer drug delivery systems. “At the forefront of our growth trajectory are our copolymer-based prefillable syringe systems, a sector that is experiencing escalating market demand and is poised to shape the future of Sharps.” Owning Manufacturing For A Market Poised For Growth Market research is forecasting significant growth within the prefillable syringe segment, with product demand outstripping supply for the foreseeable future. The market for prefilled syringes is projected to grow at a compound annual growth rate of ~12% from 2022 to 2030, according to Grand View Research. The prefilled syringe market is a niche sub-industry within the healthcare sector and Sharps will serve both Nephron and other customers within the copolymer segment of the market. Contributing to the demand for copolymer-based syringes are the glass-like features without breakage, and the market could be ripe for growth due to the global lack of capacity for these products and technical challenges in production that Sharps’ team reports a wealth of experience in. Under the terms of the deal, Sharps is paying $50 million for the InjectEZ specialty copolymer syringe manufacturing facility, which is one of the only fully dedicated facilities to manufacture these types of syringes in North America. Located on Nephron’s campus in West Columbia, South Carolina, InjectEZ has fully automated prefillable syringe system manufacturing capabilities that utilize ISO cleanrooms for all key areas including injection molding, high-speed automated assembly, and specialty packaging lines that are equipped with Husky molding machines and Hahn automation. With full control of the InjectEZ facility through this transaction and the capacity from the Company’s wholly-owned manufacturing facility in Hungary, Sharps will have the ability to supply Nephron with their prefilled syringe needs and also commercialize products to the broader healthcare syringe market. The company expects the deal to generate “significant” short and long-term revenue. Nephron Inks 10-Year Purchase Agreement As a result of this deal the Company’s first customer will be Nephron, which inked a 10-year purchase agreement for Sharps’ next-generation copolymer prefillable 10 mL and 50 mL syringes. Minimum orders will be over $400 Million during that period. Sharps expects to begin delivering products to Nephron in the first quarter of 2024, representing about $30 million in revenue for the first 12 months of production. Starting in 2025, Sharps expects revenue of at least $45 million per year through 2033 from Nephron, with additional revenue from its capacity to serve the broader market for its products. “As a company that is transitioning from research and development to commercialization, this is a significant development that will have a meaningful impact on Sharps’ revenue and profitability,'' states Mr. Hayes. We anticipate Nephron's start-up volume to be approximately 60% of our initial planned manufacturing capacity, which will provide Sharps with the ability to fully service Nephron’s needs and to also sign purchase orders for our products from other companies in the healthcare market.” To finance the acquisition of InjectEZ, Sharps retained Lampert Capital Advisors, a provider of financing solutions to public and private companies. Lampert is engaged in a financing process that has resulted in a signed term sheet with a leading middle-market lender for up to $75 Million in debt financing to be used for the acquisition of InjectEZ, production line enhancements, working capital, transaction fees and expenses, and general corporate purposes. Continuing Relationships and Growth Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 to support the manufacturing of its innovative prefillable syringe systems. Through the successful completion of the new Asset Purchase Agreement and the 10-year purchase agreement, Sharps is poised to have a full partnership and a U.S. footprint that will provide a strong baseline of revenue for Sharps for many years. The new agreement will leverage synergies from both companies and enable Sharps to commercially enter the prefilled syringe landscape with manufacturing strength and ahead of plan. These developments are the culmination of a strong partnership developed in 2022, and may be just the beginning: “We are excited about the opportunities that lie ahead as we strengthen our relationship with Nephron and will update our shareholders as the transaction advances,” said Mr. Hayes. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 06, 2023 08:50 AM Eastern Daylight Time

Sharma: India prepared for Cricket World Cup

Acroud Media

With India hosting the 2023 ICC World Cup, the Expectation is very much on the home nation to put on a good showing on home soil. India will be starting their ICC World Cup on Sunday, October 8th, against fierce opposition in five-time champions Australia. This is set to be a huge game for both sides who will be looking to start their campaign in a positive manner. Some might suggest that the host nation, India, will struggle under the weight of the pressure of being hosts, but team captain Rohit Sharma says they are ready for the tournament. Sharma says he and the team have ”prepared really well” and is used to the pressures that come with the job. "I know what is at stake,” he said. “The guys who are a part of the team know what is at stake. For us, it is about taking everything out and focussing on what we want to do as a team.” The host nation has won the Cricket World Cup in each of the last three editions and India are the betting favourites coming into the season. However, Sharma is keen for them to take it a game at a time. "It (hosts winning the WC) has happened in the last three editions of the World Cup. It is a long tournament and you cannot get too far ahead of yourself. It is important for us to try and focus on one job at a time and move on.” He added: “It is very easy to say that (forget pressure) and it is going to be tough. But we have prepared really well. As long as you have prepared really well, it gives you a lot of confidence going into the main games.” To learn more about the Cricket World Cup and the best betting apps in India, head over to Yahoo. Contact Details Acroud Media info-media@acroudmedia.com

October 06, 2023 03:00 AM Eastern Daylight Time

Image

Sonus faber choisit la technologie sans fil UWB de SPARK Microsystems pour des enceintes audio domestiques à faible latence

SPARK Microsystems

SPARK Microsystems, une entreprise canadienne de semi-conducteurs spécialisée dans les communications sans fil à courte portée de nouvelle génération, a annoncé aujourd'hui que le fabricant italien de haut-parleurs Sonus faber a choisi la technologie UWB de SPARK pour son système de haut-parleurs sans fil Duetto. La technologie UWB de SPARK permet une transmission de données à faible latence entre les enceintes filaires et les enceintes sans fil, ce qui permet à Sonus faber d'offrir une performance audio non compressée de haute qualité qui ne peut être obtenue avec Bluetooth ou Wi-Fi. Le nouveau système de haut-parleurs Duetto de Sonus faber permet aux clients de profiter de leur système audio domestique Duetto en streaming, le haut-parleur satellite de la paire stéréo étant connecté à l'unité principale à l'aide de la solution SPARK UWB. Le système prend en charge une portée allant jusqu'à 8 mètres pour une flexibilité de placement/positionnement sans compromis en termes de performance audio. Le système, certifié par l'ETSI et la Commission fédérale des communications, permet aux clients de bénéficier d'une connectivité sans fil de haute précision entre les haut-parleurs, maximisant ainsi les options de placement tout en profitant des fonctionnalités et de l'intégration des services musicaux et de la connectivité les plus performants du marché. « Le système de haut-parleurs Duetto de Sonus faber témoigne de l'évolution du marché vers un véritable système audio sans fil qui offre un son de qualité supérieure sans les fils », a déclaré Julie Delamarre, vice-présidente des ventes EMEA de SPARK Microsystems. « Le système de haut-parleurs Duetto est basé sur la technologie UWB de SPARK qui permet un transport de données à faible latence, déterministe, à faible consommation et à haut débit de données, permettant à Sonus faber de fournir un son non compressé à travers des haut-parleurs reliés sans fil - une première dans l'industrie ». L'émetteur-récepteur sans fil SPARK UWB à très faible consommation, faible latence et haut débit offre une nouvelle classe de connectivité sans fil à courte portée pour les applications audio haut de gamme. Offrant des débits de données plus élevés et une meilleure robustesse que les autres solutions sans fil à courte portée - avec une latence extrêmement faible qui ne peut être égalée par Bluetooth ou WiFi - SPARK UWB permet un son non compressé de haute-fidélité pour une expérience audio plus riche et plus immersive. « La technologie UWB de SPARK a été choisie pour le système de haut-parleurs Duetto en raison de ses capacités à délivrer un son non compressé sans fil, sans problème de latence, de variabilité ou de bande passante », déclare Livio Cucuzza, Directeur de la conception, Sonus faber. « Ces capacités offriront à nos clients une expérience supérieure, car ils pourront profiter du son tel qu'il a été conçu à l'origine par les artistes eux-mêmes, avec la flexibilité d'un couplage sans fil entre les haut-parleurs ». À propos de Sonus faber Sonus faber est un concepteur et fabricant de technologies audio haut de gamme, fondé en 1983 dans la région italienne de la Vénétie, mondialement connue pour la fabrication de produits de luxe. En latin, Sonus faber signifie "Artisan du son". L'ingénierie audio de pointe de Sonus faber s'appuie sur les traditions du design italien, en produisant à la main des enceintes dont le design s'inspire d'instruments de musique des derniers siècles, fabriqués à partir de matériaux organiques tels que le bois et le cuir, afin de reproduire le son tel que l'artiste l'a voulu. Alliant la beauté artisanale du passé à la technologie du futur, les systèmes audio Sonus faber offrent un son naturel, immersif et tridimensionnel grâce à de magnifiques enceintes conçues à la main et construites pour durer des décennies. Pour plus d'informations, veuillez consulter Sonusfaber.com. À propos de SPARK Microsystems SPARK Microsystems construit la prochaine génération de dispositifs de communication sans fil à courte portée. SPARK fournit des liens de communication sans fil à haut débit et à très faible latence avec un profil de puissance ultra-faible, ce qui le rend idéal pour les réseaux personnels (PAN) utilisés dans les produits mobiles, grand public et connectés à l’IoT. S’appuyant sur des technologies brevetées, SPARK Microsystems s’efforce de minimiser et, à terme, d’éliminer les fils et les batteries d’un large éventail d’applications. Pour plus d’informations, veuillez consulter sparkmicro.com. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://www.sparkmicro.com

October 05, 2023 10:11 AM Eastern Daylight Time

Sonus faber Chooses SPARK Microsystems’ UWB Wireless Tech for Low Latency Home Audio Speakers

SPARK Microsystems

SPARK Microsystems, a Canadian fabless semiconductor company specializing in next-generation short-range wireless communications, today announced Italian speaker manufacturer Sonus faber has chosen SPARK’s UWB technology for its Duetto wireless speaker system. SPARK’s UWB technology enables low latency data transmission from wired to wireless speakers, allowing Sonus faber to deliver a high-quality, uncompressed audio performance that can’t be achieved with Bluetooth or Wi-Fi. Sonus faber’s new Duetto speaker system enables customers to enjoy their Duetto streaming home audio system with the satellite speaker of the stereo pair being connected to the main unit using the SPARK UWB-based solution. The system supports a range up to 8 meters for unfettered placement/positioning flexibility with no compromises in audio performance. The system, certified by ETSI and the Federal Communications Commission, enables customers to enjoy high precision wireless connectivity between speakers, maximizing placement options whilst enjoying market leading functionality and integration of music services and connectivity. “Sonus faber’s Duetto speaker system demonstrates the market’s evolutionary shift to true wireless audio that delivers premium sound without the wires,” said Julie Delamarre, SPARK Microsystems, Vice President of EMEA Sales. “The Duetto speaker system is based on SPARK’s UWB technology that enables low latency, deterministic, low power, and high-speed data transport, allowing Sonus faber to deliver uncompressed audio across wirelessly-linked speakers – an industry first achievement.” The ultra-low power, low latency and high-throughput SPARK UWB wireless transceiver enables a new class of short-range wireless connectivity for premium audio applications. Offering higher data rates and better robustness than other short-range wireless solutions – with extreme low latency that can’t be matched with Bluetooth or WiFi – SPARK UWB enables high fidelity uncompressed audio for a richer, more immersive audio experience. “SPARK’s UWB technology was chosen for the Duetto speaker system because of its capabilities to deliver uncompressed audio wirelessly with no latency, variability or bandwidth concerns,” said Livio Cucuzza, Chief Design Officer, Sonus faber. “These capabilities will give our customers a superior experience because they can enjoy audio as it was originally intended by the artists themselves, with the flexibility of wireless pairing between speakers.” About Sonus faber Sonus faber is a designer and manufacturer of high-end audio technology, founded in 1983 in Italy’s Veneto region, world-renowned for luxury goods manufacturing. Latin for “Artisan of Sound”, Sonus faber expertly informs their state-of-the-art audio engineering with the traditions of Italian design expertise, hand-producing speakers with design cues inspired by centuries of musical instruments, crafted from organic materials such as wood and leather to reproduce sound as the artist intended. Marrying the artisanal beauty of the past with the technology of the future, Sonus faber audio systems deliver natural, immersive, three-dimensional sound from beautiful, hand-designed speakers built to last for decades. For more information, please visit www.sonusfaber.com. About SPARK Microsystems SPARK Microsystems is building next generation short-range wireless communication devices. SPARK provides high data rate and very low latency wireless communication links at an ultra-low power profile, making it ideal for personal area networks (PANs) used in mobile, consumer and IoT-connected products. Leveraging patented technologies, SPARK Microsystems strives to minimize and ultimately eliminate wires and batteries from a wide range of applications while delivering a wired-like performance. For more information, please visit www.sparkmicro.com. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://www.sparkmicro.com

October 05, 2023 10:08 AM Eastern Daylight Time

Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update

Benzinga

By Rachael Green, Benzinga Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, the multi-center clinical trial will have six to ten new clinical trial sites across the US. According to the Company, another key data milestone is expected soon at the ECTRIMS conference, which will detail the results from the expanded access program after six months of treatment. Investors should take note, as this is a significant event for the company through providing six-month clinical results on the second cohort of four patients (numbers 3-6), and also providing a PET scan which shows neuroinflammation in the brain (microglia). ECTRIMS is the world’s largest research meeting in multiple sclerosis and will be held October 11-13 in Milan, Italy. Tiziana also recently announced the acceptance of a publication in the prestigious journal Proceedings of the National Academy of Sciences (PNAS) of its study validating the mechanism of action (MoA) using intranasally administered foralumab in Alzheimer’s disease (AD). The published study concluded that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”, which further supports the Company’s hypothesis for the use of foralumab in neurodegenerative disease. Key highlights from the Journal included: The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s Disease The publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, ameliorates disease in a 3xTg model of Alzheimer’s disease by targeting microglial activation in the brain, while expanding regulatory T cells in the periphery Remarkably, this reduced microglial activation and improved cognition occurs independent of amyloid beta disposition. The full publication can be found HERE Tiziana’s Foralumab Is A Promising Treatment With Potential To Treat Multiple Neurological Diseases “The anti-CD3 target is established and it’s validated,” said Tiziana COO and CMO Mathew Davis at a recent conference. “We are the only company that is delivering this intranasally. We are the only company that is in the clinic with a fully human anti-CD3 antibody.” The anti-CD3 monoclonal antibody used in Tiziana’s Foralumab binds to the CD3 receptor on the surface of T cells, typically used as a way to suppress the immune system to prevent transplant rejection or treat autoimmune disease. The challenge in treating these kinds of conditions has long been finding the balance between suppressing the immune response to protect the patient without harming the body’s ability to fight off actual threats like viral infections and bacteria. However, research shows that anti-CD3 antibodies can do just that. They are able to selectively dampen the autoimmune response – when the dysregulated immune system attacks the body’s own cells and tissue – without limiting its ability to detect and respond to external threats. The promising new treatment approach has already sparked interest from pharmaceutical industry leaders like Sanofi SA (NASDAQ: SNY), which just acquired an anti-CD3 therapy being developed for type 1 diabetes in a $2.9 billion acquisition of Provention Bio, Inc. Tiziana’s Foralumab is the only anti-CD3 monoclonal antibody treatment in clinical trials that is fully human — a significant differentiator as these tend to come with fewer adverse reactions than those that are genetically engineered. It’s also the only one that’s delivered via an intranasal spray, making it less invasive than an infusion and allowing it to travel directly to the T cells in the patient’s lymph nodes. In the neurological diseases that Tiziana is focused on, this formulation has allowed its lead drug candidate to bind to regulatory T cells, then these T cells activate and create Tregs which are specifically tasked with maintaining homeostasis and preventing the immune system from attacking itself. Once Foralumab creates these Tregs, they can cross through the blood-brain barrier and help fight neuroinflammation at its source. Tiziana Highlights Past Results And Upcoming Milestones Across Foralumab Clinical Trials During a recent investor conference, Davis focused on the exciting results Tiziana has seen so far from its clinical trials and highlighted some of the upcoming milestones and plans for the year ahead. Its lead program is in non-active secondary progressive multiple sclerosis (SPMS), a more severe stage of the debilitating disease that currently has no FDA-approved treatment. Instead, the standard of care typically involves treating the patient with Ocrelizumab, an anti-CD20 monoclonal antibody sold under the brand name Ocrevus by Genentech, a subsidiary of Hoffmann-La Roche AG (OTCQX: RHHBY). But the drug is not always as effective for SPMS patients as it is for other forms of MS. In fact, Davis noted that all of the patients in its clinical trials had previously tried Ocrelizumab and discontinued it when their symptoms continued to progress. In its ongoing expanded access program, for example, the Tiziana COO and CMO spoke about a patient who had discontinued the anti-CD20 treatment in 2021 when his condition had become so bad that he could no longer walk more than 100 feet without assistance. The non-active SPMS patient enrolled in Tiziana’s expanded access program in January 2022. “By the end of 2022, he was able to walk without assistance,” Davis said. “He’s back in his job and, as of this recording, he continues to walk without assistance.” In the biopharma’s most recent data readout, other patients from the expanded access program started to show similar improvement. Three of the four patients currently enrolled saw their fatigue scores decrease after three months. Meanwhile, a phase 1 trial found that microglia – a part of the innate immune system inside the brain – had significantly decreased activation in the brains of 5 out of 6 treated patients after three months. Davis said another data readout is expected soon, detailing the results from the expanded access program after six months of treatment. Tiziana has begun clinical site selection and plans to start a phase 2a trial in non-active SPMS before the end of this year with topline data expected by the end of 2024. The clinical-stage biopharma is also investigating Foralumab for Alzheimer’s disease (AD), another progressive neurological disease with an urgent need for better treatment options. Tiziana just received FDA approval to begin a phase 2 study in AD, and the company plans to launch that trial in the first half of next year. A press release on the acceptance from the Proceedings of the National Academy of Sciences (PNAS) can be found HERE along with the full publication HERE titled “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”. To learn more about Tiziana, click HERE This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 05, 2023 09:15 AM Eastern Daylight Time

1 ... 69 70 71 72 73 ... 251